Literature DB >> 23325617

High FOXM1 expression was associated with bladder carcinogenesis.

Dongye Liu1, Zhe Zhang, Chui-ze Kong.   

Abstract

The forkhead box M1 (FOXM1) transcription factor plays crucial roles in regulating the proliferation, differentiation, and transformation of cells. Overexpression of FOXM1 is associated with a variety of aggressive solid carcinomas, including bladder cancer. However, the precise role and molecular mechanism responsible for the aggressive action of FOXM1 in bladder cancer remain unclear. Real-time quantitative PCR, Western blot and immunohistochemistry were used to explore FoxM1 expression in bladder cancer cell lines, primary bladder cancer clinical specimens and normal bladder tissues. FoxM1 expression was knocked down by small interfering RNA (siRNA) in T24 cells; proliferation, migration and invasion were assayed. FoxM1 expression was up-regulated in the majority of the bladder cancer tissue specimens at both mRNA and protein levels. Immunohistochemistry analysis showed that FoxM1 expression was significantly correlated with TNM stage and histological grade, metastasis. Experimentally, we found that down-regulation of FoxM1 inhibited cell proliferation, migration and invasion. These results suggested that FOXM1 up-regulation was associated with poor prognosis in bladder cancer, and therefore it might act as a prognostic marker and a new potential target for bladder cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23325617     DOI: 10.1007/s13277-013-0654-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  28 in total

Review 1.  Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.

Authors:  Maddalena Frau; Fiorella Biasi; Francesco Feo; Rosa M Pascale
Journal:  Mol Aspects Med       Date:  2010-02-20

2.  FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.

Authors:  Nu Zhang; Xinjian Wu; Lixuan Yang; Feizhe Xiao; Heng Zhang; Aidong Zhou; Zhengsong Huang; Suyun Huang
Journal:  Clin Cancer Res       Date:  2012-09-12       Impact factor: 12.531

3.  The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism.

Authors:  Xi Chen; Gerd A Müller; Marianne Quaas; Martin Fischer; Namshik Han; Benjamin Stutchbury; Andrew D Sharrocks; Kurt Engeland
Journal:  Mol Cell Biol       Date:  2012-10-29       Impact factor: 4.272

4.  Renal neoplasms in younger adults: analysis of 112 tumors from a single institution according to the new 2004 World Health Organization classification and 2002 American Joint Committee on Cancer Staging System.

Authors:  Ying Cao; Gladell P Paner; Kent T Perry; Robert C Flanigan; Steven C Campbell; Maria M Picken
Journal:  Arch Pathol Lab Med       Date:  2005-04       Impact factor: 5.534

5.  Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Limin Xia; Wenjie Huang; Dean Tian; Hongwu Zhu; Yongguo Zhang; Hao Hu; Daiming Fan; Yongzhan Nie; Kaichun Wu
Journal:  J Hepatol       Date:  2012-05-18       Impact factor: 25.083

6.  A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis.

Authors:  Chen Huang; Zhengjun Qiu; Liwei Wang; Zhihai Peng; Zhiliang Jia; Craig D Logsdon; Xiangdong Le; Daoyan Wei; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2011-12-22       Impact factor: 12.701

7.  High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.

Authors:  Zhe Zhang; Guojun Zhang; Chuize Kong
Journal:  Urol Oncol       Date:  2011-12-20       Impact factor: 3.498

8.  Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells.

Authors:  Zhiwei Wang; Yiwei Li; Aamir Ahmad; Sanjeev Banerjee; Asfar S Azmi; Dejuan Kong; Christine Wojewoda; Lucio Miele; Fazlul H Sarkar
Journal:  J Cell Biochem       Date:  2011-01       Impact factor: 4.429

9.  FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.

Authors:  Richard E Francis; Stephen S Myatt; Janna Krol; Johan Hartman; Barrie Peck; Ursula B McGovern; Jun Wang; Stephanie K Guest; Aleksandra Filipovic; Ondrej Gojis; Carlo Palmieri; David Peston; Sami Shousha; Qunyan Yu; Piotr Sicinski; R Charles Coombes; Eric W-F Lam
Journal:  Int J Oncol       Date:  2009-07       Impact factor: 5.650

Review 10.  Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting.

Authors:  Ruta Gupta; Gladell P Paner; Mahul B Amin
Journal:  Adv Anat Pathol       Date:  2008-05       Impact factor: 3.875

View more
  16 in total

1.  Downregulation of FoxM1 inhibits cell growth and migration and invasion in bladder cancer cells.

Authors:  Xinping Yang; Yuanyuan Shi; Jingzhe Yan; Haitao Fan
Journal:  Am J Transl Res       Date:  2018-02-15       Impact factor: 4.060

2.  Forkhead box protein M1 predicts outcome in human osteosarcoma.

Authors:  Chong-Lang Fan; Jian Jiang; Hu-Cheng Liu; Dong Yang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Low level of FOXL1 indicates a worse prognosis for gastric cancer patients.

Authors:  Zhai Ertao; Chen Jianhui; Chen Chuangqi; Qin Changjiang; Chen Sile; He Yulong; Cai Shirong; Wu Hui
Journal:  Tumour Biol       Date:  2016-03-09

4.  ncRuPAR inhibits gastric cancer progression by down-regulating protease-activated receptor-1.

Authors:  Long Liu; Bing Yan; Zhihui Yang; Xiaodong Zhang; Qunhao Gu; Xiaoqiang Yue
Journal:  Tumour Biol       Date:  2014-05-12

5.  Overexpression of stathmin 1 is associated with poor prognosis of patients with gastric cancer.

Authors:  Bin Ke; Liang-Liang Wu; Ning Liu; Ru-Peng Zhang; Chang-Li Wang; Han Liang
Journal:  Tumour Biol       Date:  2013-06-13

6.  Decreased expression of IGFBP7 was a poor prognosis predictor for gastric cancer patients.

Authors:  Long Liu; Zhihui Yang; Weixing Zhang; Bing Yan; Qunhao Gu; Jianpeng Jiao; Xiaoqiang Yue
Journal:  Tumour Biol       Date:  2014-06-04

7.  FOXM1 participates in PLK1-regulated cell cycle progression in renal cell cancer cells.

Authors:  Zhe Zhang; Guojun Zhang; Chuize Kong
Journal:  Oncol Lett       Date:  2016-02-15       Impact factor: 2.967

8.  FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.

Authors:  Zuhal Hamurcu; Ahmed Ashour; Nermin Kahraman; Bulent Ozpolat
Journal:  Oncotarget       Date:  2016-03-29

9.  FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.

Authors:  Franziska Briest; Erika Berg; Irina Grass; Helma Freitag; Daniel Kaemmerer; Florentine Lewens; Friederike Christen; Ruza Arsenic; Annelore Altendorf-Hofmann; Almut Kunze; Jörg Sänger; Thomas Knösel; Britta Siegmund; Michael Hummel; Patricia Grabowski
Journal:  Oncotarget       Date:  2015-04-10

10.  FoxM1 is a promising candidate target in the treatment of breast cancer.

Authors:  Xiao-Feng Lu; Wei-Quan Liang; Chun-Fa Chen; Shu-Ming Sun; Hao-Yu Lin
Journal:  Oncotarget       Date:  2017-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.